提高卒中或TIA后二级预防用药依从性可改善生存:一项链接登记研究
该回顾性队列研究纳入澳大利亚卒中临床登记中8363例首发卒中或TIA后1年存活者,链接全国处方配药与死亡数据,分析出院后第一年用药依从性与3年内全因死亡的关系。结果显示,在依从性超过60%的线性区间内,降压药、他汀和非阿司匹林抗血栓药每增加10%依从性,全因死亡风险分别降低13%、13%和15%。
要点
- 卒中或TIA后第一年用药依从性越高,3年内生存越好。
- 依从性超过60%后,每提高10%依从性死亡风险约降13%–15%。
- 非阿司匹林抗血栓药仅在依从性高于60%的区间与生存改善相关。
核心结论
- 卒中或TIA后更高的用药依从性与改善的生存相关,即使依从性接近完美者亦然。
- 需要干预以提高用药依从性,从而最大化卒中后生存。
研究设计与样本
- 澳大利亚卒中临床登记(2010年7月至2014年6月)中首发卒中或TIA后1年存活者,年龄≥18岁,链接全国处方配药与死亡数据(至2017年8月)。
- 共8363例1年存活者,44%年龄≥75岁,44%女性,18%为TIA。
- 依从性按出院至1年的覆盖天数比例计算,采用限制性立方样条Cox回归分析至出院后3年的全因死亡。
- 模型调整年龄、性别、社会经济地位、卒中因素、初级保健因素和合并用药。
主要发现
- 75%的患者被供应降压药;在无脑出血患者(N=7446)中,84%被供应他汀,65%被供应非阿司匹林抗血栓药。
- 各类药物依从性中位数约为90%。
- 在1%至100%依从性范围内,他汀或降压药依从性越高与生存改善相关,非阿司匹林抗血栓药未见此关联。
关键数值与推荐
- 在依从性高于60%的线性区间,降压药每增加10%依从性,全因死亡风险降低13%(HR 0.87 [95%CI 0.81–0.95])。
- 他汀每增加10%依从性,全因死亡风险降低13%(HR 0.87 [95%CI 0.80–0.95])。
- 非阿司匹林抗血栓药每增加10%依从性,全因死亡风险降低15%(HR 0.85 [95%CI 0.79–0.93])。
临床怎么用
- 对卒中或TIA后患者应评估并干预降压药、他汀和非阿司匹林抗血栓药的依从性。
- 依从性目标不应止于80%,在超过60%后继续提高依从性仍与生存改善相关。
局限性
- 为回顾性队列研究,依从性基于处方配药覆盖天数,可能不能完全反映实际服药。
- 非阿司匹林抗血栓药仅在高于60%依从性区间与生存相关,整体关联不显著。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Although a target of 80% medication adherence is commonly cited, it is unclear whether greater adherence improves survival after stroke or transient ischemic attack (TIA). We investigated associations between medication adherence during the first year postdischarge, and mortality up to 3 years, to provide evidence-based targets for medication adherence. METHODS: Retrospective cohort study of 1-year survivors of first-ever stroke or TIA, aged ≥18 years, from the Australian Stroke Clinical Registry (July 2010–June 2014) linked with nationwide prescription refill and mortality data (until August 2017). Adherence to antihypertensive agents, statins, and nonaspirin antithrombotic medications was based on the proportion of days covered from discharge until 1 year. Cox regression with restricted cubic splines was used to investigate nonlinear relationships between medication adherence and all-cause mortality (to 3 years postdischarge). Models were adjusted for age, sex, socioeconomic position, stroke factors, primary care factors, and concomitant medication use. RESULTS: Among 8363 one-year survivors of first-ever stroke or TIA (44% aged ≥75 years, 44% female, 18% TIA), 75% were supplied antihypertensive agents. In patients without intracerebral hemorrhage (N=7446), 84% were supplied statins, and 65% were supplied nonaspirin antithrombotic medications. Median adherence was ≈90% for each medication group. Between 1% and 100% adherence, greater adherence to statins or antihypertensive agents, but not nonaspirin antithrombotic agents, was associated with improved survival. When restricted to linear regions above 60% adherence, each 10% increase in adherence was associated with a reduction in all-cause mortality of 13% for antihypertensive agents (hazard ratio, 0.87 [95% CI, 0.81–0.95]), 13% for statins (hazard ratio, 0.87 [95% CI, 0.80–0.95]), and 15% for nonaspirin antithrombotic agents (hazard ratio, 0.85 [95% CI, 0.79–0.93]). CONCLUSIONS: Greater levels of medication adherence after stroke or TIA are associated with improved survival, even among patients with near-perfect adherence. Interventions to improve medication adherence are needed to maximize survival poststroke.
引用
- Dalli LL, Kim J, Cadilhac DA, et al. Greater Adherence to Secondary Prevention Medications Improves Survival After Stroke or Transient Ischemic Attack: A Linked Registry Study. Stroke. 2021. PMID: 34315251. doi:10.1161/STROKEAHA.120.033133
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。